Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00734877 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

Study acronym: TT4B
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 2026 to Sep 2027
    • Study completion date: Sep 2027 to Sep 2028
    v29
  2. Primary completion date: Sep 2025 to Sep 2026
    • Study completion date: Sep 2026 to Sep 2027
    v28
  3. Primary completion date: Sep 2024 to Sep 2025
    • Study completion date: Sep 2024 to Sep 2026
    v27
  4. Primary and study completion dates: Sep 2023 to Sep 2024v26
  5. Primary and study completion dates: Sep 2022 to Sep 2023v25
Show 23 earlier versionsHide 23 earlier versions
  1. Primary and study completion dates: Sep 2021 to Sep 2022v24
  2. Primary and study completion dates: Sep 2020 to Sep 2021v23
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 400 to confirmed 382
    • Site details revised
    v22
  4. Primary and study completion dates: Sep 2019 to Sep 2020v21
  5. Primary and study completion dates: Sep 2017 to Sep 2019v20
  6. Primary and study completion dates: Sep 2016 to Sep 2017
    • Site contact updated
    v19
  7. Primary endpoint revisedv18 Show 4 more changesShow less
    • Enrollment target: 350 to 400
    • Secondary endpoints shortened, about 32 words
    • Study description expanded, about 27 words
    • Study title expanded, about 3 words
  8. Re-verified, no change to tracked fieldsv17
  9. Site contact updatedv16
  10. Primary and study completion dates: Sep 2015 to Sep 2016
    • Site contact updated
    v15
  11. Site contact updatedv14
  12. Primary and study completion dates: Sep 2014 to Sep 2015
    • Site contact updated
    v13
  13. Site contact updatedv12
  14. Primary and study completion dates: Sep 2013 to Sep 2014
    • Site contact updated
    v11
  15. Primary and study completion dates: Jan 2013 to Sep 2013
    • Site contact updated
    v10
  16. Site contact updatedv9
  17. Primary completion date: Jan 2012 to Jan 2013
    • Site contact updated
    v8
  18. Site contact updatedv7
  19. Primary completion date: Jan 2011 to Jan 2012
    • Study completion date: Jan 2012 to Jan 2013
    • Site contact updated
    v6
  20. Site contact updatedv5
  21. Re-verified, no change to tracked fieldsv4
  22. Site contact updatedv3
  23. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to determine whether S-TT3 treatment-related toxicities can be reduced by 50% in TT3-Lite (L-TT3). Note: Randomization has been discontinued and accrual is closed to the L-TT3 arm. This trial is currently enrolling as a single-arm trial for patients to receive S-TT3.
Trial Details
NCT Number NCT00734877
Lead Sponsor University of Arkansas
Collaborators: Millennium Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 382 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov